| Dr Margit Szabo Lister, MD | |
|
2400 N Washington Blvd, Ogden, UT 84414-7233 | |
| (801) 786-7500 | |
| (801) 737-9531 |
| Full Name | Dr Margit Szabo Lister |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 25 Years |
| Location | 2400 N Washington Blvd, Ogden, Utah |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528098571 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 62287191205 (Utah) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
A research group led by Kobe University Professor MORIOKA Ichiro (Graduate School of Medicine, Department of Pediatrics), Associate Professor OSAWA Kayo (Graduate School of Health Sciences, Department of Biophysics), and Clinical Technologist SATO Itsuko (Kobe University Hospital, Department of Clinical Laboratory) is proposing a new criterion for diagnosis of bacterial infection in preterm infants.
Men and women worry about prostate and breast cancer, yet the number one cancer killer in the United States – lung cancer – isn't on their radar. According to a survey released today by the National Lung Cancer Partnership, Americans know little about lung cancer's causes, symptoms and the number of lives it takes compared to other cancers.
Researchers at Dana-Farber Cancer Institute have shown that advanced pancreatic cancers in mice can't survive without continued expression of a mutant oncogene that "rewires" key metabolic pathways to fuel the cancer cells.
Heavy beer drinkers who have a specific genetic variant in the cluster of three genes that metabolize alcohol are at significantly higher risk of developing non-cardia gastric cancer, according to research presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.
Chugai Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved HEMLIBRA (US generic name: emicizumab-kxwh), a treatment for hemophilia A created by Chugai, for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A without factor VIII inhibitors, administered once weekly, every two weeks, or every four weeks.
› Verified 2 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942325154 PECOS PAC ID: 1850209420 Enrollment ID: O20080610000303 |
News Archive
A research group led by Kobe University Professor MORIOKA Ichiro (Graduate School of Medicine, Department of Pediatrics), Associate Professor OSAWA Kayo (Graduate School of Health Sciences, Department of Biophysics), and Clinical Technologist SATO Itsuko (Kobe University Hospital, Department of Clinical Laboratory) is proposing a new criterion for diagnosis of bacterial infection in preterm infants.
Men and women worry about prostate and breast cancer, yet the number one cancer killer in the United States – lung cancer – isn't on their radar. According to a survey released today by the National Lung Cancer Partnership, Americans know little about lung cancer's causes, symptoms and the number of lives it takes compared to other cancers.
Researchers at Dana-Farber Cancer Institute have shown that advanced pancreatic cancers in mice can't survive without continued expression of a mutant oncogene that "rewires" key metabolic pathways to fuel the cancer cells.
Heavy beer drinkers who have a specific genetic variant in the cluster of three genes that metabolize alcohol are at significantly higher risk of developing non-cardia gastric cancer, according to research presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.
Chugai Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved HEMLIBRA (US generic name: emicizumab-kxwh), a treatment for hemophilia A created by Chugai, for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A without factor VIII inhibitors, administered once weekly, every two weeks, or every four weeks.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Margit Szabo Lister, MD Po Box 27128, Salt Lake City, UT 84127-0128 Ph: (801) 786-7500 | Dr Margit Szabo Lister, MD 2400 N Washington Blvd, Ogden, UT 84414-7233 Ph: (801) 786-7500 |
News Archive
A research group led by Kobe University Professor MORIOKA Ichiro (Graduate School of Medicine, Department of Pediatrics), Associate Professor OSAWA Kayo (Graduate School of Health Sciences, Department of Biophysics), and Clinical Technologist SATO Itsuko (Kobe University Hospital, Department of Clinical Laboratory) is proposing a new criterion for diagnosis of bacterial infection in preterm infants.
Men and women worry about prostate and breast cancer, yet the number one cancer killer in the United States – lung cancer – isn't on their radar. According to a survey released today by the National Lung Cancer Partnership, Americans know little about lung cancer's causes, symptoms and the number of lives it takes compared to other cancers.
Researchers at Dana-Farber Cancer Institute have shown that advanced pancreatic cancers in mice can't survive without continued expression of a mutant oncogene that "rewires" key metabolic pathways to fuel the cancer cells.
Heavy beer drinkers who have a specific genetic variant in the cluster of three genes that metabolize alcohol are at significantly higher risk of developing non-cardia gastric cancer, according to research presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.
Chugai Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved HEMLIBRA (US generic name: emicizumab-kxwh), a treatment for hemophilia A created by Chugai, for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A without factor VIII inhibitors, administered once weekly, every two weeks, or every four weeks.
› Verified 2 days ago
Wesley Boyd Davis, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1525 E 6000 S, Ogden, UT 84405 Phone: 801-337-5800 Fax: 801-337-5809 | |
Dr. Sara Elizabeth Wood, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 4403 Harrison Blvd, Ste 4815, Ogden, UT 84403 Phone: 801-387-8350 Fax: 801-387-8355 | |
Dr. Azadeh E Poursaid, MD, PHD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1525 E 6000 S Ste A, Ogden, UT 84405 Phone: 801-337-5800 Fax: 801-337-5809 | |
Dr. John David Lesser Ii, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 4403 Harrison Blvd, Suite 4650, Ogden, UT 84403 Phone: 801-387-4400 Fax: 801-387-4410 | |
Dr. Steve F Johnson, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 4647 Madison Ave, Ogden, UT 84403 Phone: 801-479-1537 | |
Dr. Rodney Stephen Merrill, DO Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 434 E 5350 S, Suite A, Ogden, UT 84405 Phone: 801-479-1641 Fax: 801-476-8538 | |
Alexander J Larson, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 5495 S 500 E, Ste 310, Ogden, UT 84405 Phone: 801-475-3100 Fax: 801-475-3101 |